Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX™/Doxil®) versus conventional doxorubicin for first-line treatment of metastatic breast cancer

Annals of Oncology

Volumn 15, Issue 3, 2004, Pages 440-449

  O'Brien, Mary E R ^a,l   Wigler, N ^b   Inbar, M ^b   Rosso, R ^c   Grischke, E ^d   Santoro, A ^e   Catane, R ^f   Kieback, D G ^g   Tomczak, P ^h   Ackland, S P ⁱ   Orlandi, F ^j   Mellars, L ^k   Alland, L ^k   Tendler, C ^k  

^a Kent Cancer Centre   (United Kingdom)

^b TEL AVIV SOURASKY MEDICAL CENTER   (Israel)

^c Oncologia Medica B   (Italy)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

^f SHAARE ZEDEK MEDICAL CENTER   (Israel)

^g MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^h Oncology Clinic   (Poland)

ⁱ NEWCASTLE MATER HOSPITAL   (Australia)

^j HOSPITAL DIPRECA   (Chile)

^k MERCK RESEARCH LABORATORIES   (United States)

^l ROYAL MARSDEN HOSPITAL   (United Kingdom)

more..

Author keywords

Cardiotoxicity; Pegylated liposomal doxorubicin

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTIEMETIC AGENT; BILIRUBIN; BISPHOSPHONIC ACID DERIVATIVE; DOXORUBICIN; GROWTH FACTOR; LIPOSOME; SEROTONIN 3 ANTAGONIST;

ABDOMINAL CANCER; ABDOMINAL PAIN; ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; ASTHENIA; BILIRUBIN BLOOD LEVEL; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE METASTASIS; BRAIN METASTASIS; BREAST CANCER; CANCER GROWTH; CANCER SURVIVAL; CARDIOTOXICITY; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONGESTIVE HEART FAILURE; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG SAFETY; DYSPNEA; ERYTHEMA; FATIGUE; FEMALE; FEVER; HAND FOOT SYNDROME; HAZARD ASSESSMENT; HEART ARREST; HEART DISEASE; HEART FUNCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LEUKOPENIA; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MOUTH ULCER; MUCOSA INFLAMMATION; MULTICENTER STUDY; MUSCLE WEAKNESS; NAUSEA; NEUTROPENIA; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PIGMENT DISORDER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SEPSIS; SIDE EFFECT; STATISTICAL ANALYSIS; STOMATITIS; SURVIVAL TIME; TACHYPNEA; THROMBOCYTOPENIA; VOMITING;

EID: 11144357506     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh097     Document Type: Article

References (25)

1. Polychemotherapy for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet 1998; 352: 930-942.
2. Joensuu H, Holli K, Heikkinen M et al. Combination chemotherapy versus single-agent therapy as first- and second-line treatment in metastatic breast cancer: A prospective randomized trial. J Clin Oncol 1998; 16: 3720-3730.
3. Chlebowski RT, Smalley RV, Weiner JM et al. Combination versus sequential single agent chemotherapy in advanced breast cancer: associations with metastatic sites and long-term survival. The Western Cancer Study Group and The Southeastern Cancer Study Group. Br J Cancer 1989; 59: 227-230.
4. Smith G, Henderson IC. New treatments for breast cancer. Semin Oncol 1996; 23: 506-528.
5. Symon Z, Peyser A, Tzemach D et al. Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes. Cancer 1999; 86: 72-78.
6. Gordon AN, Fleagle JT, Guthrie D et al. Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J Clin Oncol 2001; 19: 3312-3322.
7. Gabizon A, Martin F. Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs 1997; 54: 15-21.
8. Ranson MR, Carmicheal J, O'Byrne K et al. Treatment of advanced breast cancer with sterically stabilized liposomal doxorubicin: results of a multicenter phase II trial. J Clin Oncol 1997; 15: 3185-3191.
9. Fleming I, Cooper J, Henson D et al. AJCC Cancer Staging Manual, 5th edition. Philadelphia, PA: Lippincott-Raven 1997.
10. Miller AB, Hoogstraten B, Staquet M et al. Reporting results of cancer treatment. Cancer 1981; 47: 207-214.
11. Common Toxicity Criteria, version 2.0. Bethesda, MA: National Cancer Institute 1998.
12. Singal PK, Iliskovic N. Doxorubicin-induced cardiomyopathy. N Engl J Med 1998; 339:900-905.
13. Von Hoff DD, Layard MW, Basa P et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 1979; 91: 710-717.
14. Titgan M. Prevention of palmar-plantar erythrodysesthesia associated with liposome-encapsulated doxorubicin (Doxil) by oral dexamethasone. Proc Am Soc Clin Oncol 1997; 16: 288a.
15. Vail DM, Chun R, Thamm DH et al. Efficacy of pyridoxine to ameliorate the cutaneous toxicity associated with doxorubicin containing pegylated (Stealth) liposomes: A randomized, double-blind clinical trial using a canine model. Clin Cancer Res 1998; 4: 1567-1571.
16. Honecker F, Mayer F, Hilger R et al. Reduction of skin toxicity of pegylated lipsomal doxorubicin (PLD) by concomitant administration of dexamethasone and pyridoxine (PYR) in patients (PTS) with anthracycline-sensitive malignancies: A phase I/II trial. J Cancer Res Clin Oncol 2002; 128 (Suppl): 848.
17. Baas P, van Meerbeeck J, Groen H et al. Caelyx in malignant mesothelioma: A phase II EORTC study. Ann Oncol 2000; 11: 697-700.
18. Israel VP, Garcia AA, Roman L et al. Phase II study of liposomal doxorubicin in advanced gynecologic cancer Gynecol Oncol 2000; 78: 143-147.
19. Muggia FM, Blessing JA, Sorosky J et al. Phase II trial of the pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: A Gynecologic Oncology Group Study. J Clin Oncol 2002; 20: 2360-2364.
20. 2. Ann Oncol 2000; 11: 1029-1033.
21. Torti FM, Bristow MM, Lum BL et al. Cardiotoxicity of epirubicin and doxorubicin: Assessment by endomyocardial biopsy. Cancer Res 1986; 46: 3722-3727.
22. Jain KK, Casper ES, Geller NL et al. A prospective randomized comparison of epirubicin and doxorubicin in patients with advanced breast cancer. J Clin Oncol 1985; 3: 818-826.
23. Epirubicin-based chemotherapy in metastatic breast cancer patients: Role of dose-intensity and duration of treatment. J Clin Oncol 2000; 18: 3115-3124.
24. Harris L, Batist G, Belt R et al. Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 2002; 94: 25-36.
25. Batist G, Ramakrishnan G, Rao CS et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer. J Clin Oncol 2001; 19: 1444-1454.